An author of a study in the May 2021 issue of The American Journal of Managed Care® describes how the COVID-19 pandemic, the aging of America, and already-existing workforce shortages will further threaten the dual-eligible population unless policy makers reform scope-of-practice laws.
Triple forces are combining to create a crisis for the nation’s dual-eligible beneficiaries—that is, individuals who are covered under both Medicare and Medicaid. They tend to have multiple, chronic, costly medical conditions and have very low incomes.
In the May issue of The American Journal of Managed Care®, Wendy Y. Xu, PhD; Sheldon M. Retchin, MD, MSPH; and Peter Buerhaus, PhD, RN, published a study showing how states with the most restrictive scope-of-practice laws have an inadequate supply of primary care clinicians to serve areas with a high concentration of these vulnerable beneficiaries.
In this episode of Managed Care Cast, Xu describes how the COVID-19 pandemic, the aging of America, and already-existing workforce shortages will further threaten this population unless policy makers reform scope-of-practice laws.
Listen above or through one of these podcast services:
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More